Armis Advisers’s Halozyme HALO Stock Holding History

Armis Advisers’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,177	Closed	-$295K	–	432
2024 Q4	$295K	Buy	+6,177	New	+$317K	0.04%	268

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armis Advisers's HALO Position: Q1 2025 in Review

Armis Advisers sold out of Halozyme (HALO) in Q1 2025, closing a stake of 6,177 shares — an estimated $295K sold.

Armis Advisers first reported a position in HALO in Q4 2024 and held it in 1 quarter. The position peaked at $295K in Q4 2024. 550 funds tracked by Wall St. Rank hold HALO as of Q1 2025.

Armis Advisers reported no remaining Halozyme position as of Q1 2025 after selling out during the quarter.
Armis Advisers sold 6,177 Halozyme shares in Q1 2025, an estimated $295K.
Armis Advisers first reported a position in Halozyme in Q4 2024 and held it in 1 quarter.
Armis Advisers's Halozyme position peaked at $295K in Q4 2024.
550 funds tracked by Wall St. Rank held Halozyme as of Q1 2025.

Based on Armis Advisers's 13F filing for Q1 2025, filed 8 May 2025.